Pluri Inc.'s subsidiary, Cellav Health and Aesthetics Ltd., has completed cosmetic regulatory registration in the UK for its regenerative aesthetics product, Regenativo+. This registration allows Cellav to market the product commercially in the UK, a market estimated at $900 million annually, and supports the company's broader international expansion strategy. The product leverages Pluri's 3D cell-expansion technology and advanced bioactive ingredients for professional aesthetic use. Cellav is also advancing commercial discussions in the UK and pursuing further regulatory approvals globally to expand its presence in the regenerative aesthetics and longevity markets.
Investors seeking reliable passive income and total returns should consider four high-yield dividend stocks highlighted for their strong dividends and growth prospects. General Mills, International Paper, PepsiCo, and UPS all offer dividend yields ab...
Strategy raised $333.7 million by selling 3.46 million shares of common stock but made no bitcoin transactions, keeping its bitcoin holdings steady at 840,447 BTC. The company used part of the proceeds to repurchase $132.2 million of preferred stock,...
SpaceX (SPCX) is expected to see significant demand driven by index inclusion as its free float increases after the 180-day post-IPO lock-up expires in September 2026. Major institutional holders like Nvidia, Alphabet, and Fidelity currently hold sha...
Bitcoin's 30-day realized volatility has dropped to 21.80%, the lowest since October 2025, indicating calm price movements. However, the 30-day implied volatility remains near 36%, keeping Bitcoin options expensive despite the stable spot market. Thi...
Health insurer Centene announced that CFO Drew Asher will step down in December 2026 and retire by the end of 2027. Chris Neczypor, formerly CFO at Lincoln Financial, will join Centene in September 2026 and take over as CFO on January 1, 2027. This l...
